RNF43 deficiency activates YBX1-MYC-driven oxidative phosphorylation in pancreatic cancer
Open Access
- 5 May 2026
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 652, 218560
Abstract
No abstract availableKeywords
Funding Information
- Wuhan Union Hospital
- National Natural Science Foundation of China (82573059)
- National Natural Science Foundation of China (82303358)
- National Natural Science Foundation of China (82103611)
- National Natural Science Foundation of China (82573316)
This publication has 35 references indexed in Scilit:
- First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumorsInvestigational New Drugs, 2022
- Characterization of RNF43 frameshift mutations that drive Wnt ligand‐ and R‐spondin‐dependent colon cancerThe Journal of Pathology, 2022
- Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patientsCell, 2022
- Deficient Rnf43 potentiates hyperactive Kras‐mediated pancreatic preneoplasia initiation and malignant transformationAnimal Models and Experimental Medicine, 2022
- Transient phases of OXPHOS inhibitor resistance reveal underlying metabolic heterogeneity in single cellsCell Metabolism, 2021
- Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 PathwayMolecular Therapy-Oncolytics, 2020
- Role of post-translational modification of the Y box binding protein 1 in human cancersGenes & Diseases, 2015
- YB‐1 protein: functions and regulationWIREs RNA, 2013
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose MetabolismCell, 2012
- The pleiotropic functions of the Y‐box‐binding protein, YB‐1BioEssays, 2003